Inclusion criteria :

1. Patients must have histologically confirmed unresectable advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), triple negative breast cancer (TNBC), esophageal squamous cell cancer (ESCC), bladder cancer (BC), vulvar cancer (VC) and cervical cancer (CC) and have no remaining standard treatment options (including those who have failed or are intolerant to standard therapy).
2. Patients ≥18 years of age and over the legal age of consent as required by local legislation at the time of signature of the informed consent form (ICF).
3. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
4. Patient must have at least one measurable lesion outside of the central nervous system (CNS) as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Tumour lesions that have been irradiated ≥28 days before the start of treatment, and have subsequently had documented progression, may be chosen as measurable lesions only in the absence of measurable lesions that have not been irradiated.
5. Further inclusion criteria apply.

Exclusion criteria :

1. Prior treatment with systemic anticancer drugs within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of study intervention.

2. Treatment with extensive field radiotherapy including whole brain irradiation within 14 days prior to first administration.

3. Patient has a diagnosis of immunodeficiency other than human immunodeficiency virus (HIV).

4. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of III or IV, corrected QT (QTc) prolongation > 480 msec, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the Investigator.

   Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to treatment.

5. Further exclusion criteria apply.